Engineered interferon-beta proteins

Engineered interferon-beta proteins with specific amino acid substitutions address the limitations of wildtype interferon-beta proteins by enhancing their biological activity and receptor binding affinity, resulting in improved therapeutic efficacy for conditions like multiple sclerosis and cancers.

WO2025059390A2 Publication Date: 2025-03-20HELIGENICS INC
0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2024/046509
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-09-12
Filing Date
2024-09-12
Publication Date
2025-03-20

AI Technical Summary

Technical Problem

Current interferon-beta proteins have limitations in terms of biological activity, specifically in their ability to effectively bind and activate interferon-α/β receptors, leading to suboptimal therapeutic outcomes in conditions such as multiple sclerosis and cancers.

Method used

Engineered interferon-beta proteins with specific amino acid substitutions, as listed in Table 1, are developed to enhance their biological activity. These substitutions increase the proteins' ability to bind and activate IFNAR1 or IFNAR2 subunits, leading to improved signaling activity compared to wildtype interferon-beta proteins.

Benefits of technology

The engineered interferon-beta proteins demonstrate increased biological activity, including enhanced expression of biological targets and improved binding affinity to interferon receptors, which translates to more effective reduction of pro-inflammatory cytokines and increased levels of anti-inflammatory cytokines, ultimately leading to reduced inflammation in treated subjects.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Disclosed herein are engineered interferon-beta (IFN-beta) protein proteins having increased biological activity, relative to a wildtype IFN-beta protein. Also disclosed herein are vectors encoding the engineered IFN-beta protein variants described herein. Also disclosed herein are pharmaceutical compositions comprising the engineered IFN-beta protein variants described herein or a vector encoding the engineered IFN-beta protein variants described herein. Also disclosed herein are methods of treating a disease by administering to a subject the engineered IFN-beta protein variants described herein, a vector encoding the engineered IFN-beta protein variants described herein, or a pharmaceutical composition comprising the engineered IFN-beta protein variants described herein or a vector described herein.
Need to check novelty before this filing date? Find Prior Art